Braking bad: blockade of inhibitory pathways improves interleukin-15 therapy

Clin Cancer Res. 2010 Dec 15;16(24):5917-9. doi: 10.1158/1078-0432.CCR-10-2658. Epub 2010 Oct 29.

Abstract

Blockade of the CTLA-4 and PD-1 inhibitory pathways in T cells via the administration of neutralizing antibodies at the time of interleukin (IL)-15 therapy markedly enhanced the survival of tumor-bearing mice as compared with those receiving IL-15 alone or IL-15 in combination with just one of the antibodies.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antibodies, Neutralizing / administration & dosage
  • Antibodies, Neutralizing / pharmacology*
  • Antigens, CD / immunology
  • Antigens, CD / metabolism
  • Antigens, CD / physiology
  • Antigens, Differentiation / immunology
  • Antigens, Differentiation / metabolism
  • Antigens, Differentiation / physiology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CTLA-4 Antigen
  • Cell Line, Tumor
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Drug Synergism
  • Immune Tolerance / drug effects*
  • Immune Tolerance / immunology
  • Immunotherapy / methods
  • Interleukin-15 / therapeutic use*
  • Mice
  • Models, Biological
  • Neoplasm Metastasis
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / mortality
  • Neoplasms / pathology
  • Programmed Cell Death 1 Receptor
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • Treatment Outcome

Substances

  • Antibodies, Neutralizing
  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Interleukin-15
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor